Apolipoprotein E genotype and early Alzheimer's disease: A longitudinal SPECT study

Journal of Neuroimaging

Volumn 13, Issue 2, 2003, Pages 113-123

  Sakamoto, Shigeki ^a,c   Matsuda, Hiroshi ^a   Asada, Takashi ^b   Ohnishi, Takashi ^a   Nakano, Seigo ^a   Kanetaka, Hidekazu ^a,c   Takasaki, Masaru ^c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Apolipoprotein E; Partial volume effects; Regional cerebral blood flow; Singlephoton emission computed tomography

Indexed keywords

APOLIPOPROTEIN E; CYSTEINE ETHYL ESTER TC 99M;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; CINGULATE GYRUS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; FRONTAL CORTEX; GENOTYPE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; MALE; MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BRAIN; CEREBROVASCULAR CIRCULATION; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; REGIONAL BLOOD FLOW; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0037381283     PISSN: 10512284     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003251171     Document Type: Article

References (47)

1. Weisgraber KH. Apolipoprotein E: structure-function relationship. Adv Protein Chem 1994;45:249-302.
2. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
3. Yamagata Z, Asada T, Kinoshita A, Zhang Y, Asaka A. Distribution of apolipoprotein E gene polymorphisms in Japanese patients with Alzheimer's disease and in Japanese centenarians. Hum Hered 1997;47:22-26.
4. Nagy ZS, Esiri MM, Jobst KA, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995;69:757-761.
5. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein. N Engl J Med 1995;333:1242-1247.
6. Bales KR, Verina T, Dodel RC, et al. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nature Genet 1997;17:263-264.
7. Frackowiak RSJ, Friston KJ, Frith CD, Dolan RJ, Mazziotta JC. Human brain function. San Diego, Calif: Academic Press; 1997.
8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984;34:939-944.
9. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
10. Hodges JR. Cognitive assessment for clinicians. Oxford, England: Oxford Medical Publications; 1993.
11. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
12. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
13. Wechsler D. Wechsler Memory Scale-Revised manual. San Antonio, Tex: The Psychological Corporation; 1987.
14. Wechsler D. The Wechsler Adult Intelligence Scale-Revised. New York, NY: The Psychological Corporation; 1981.
15. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
16. Asada T, Yamagata Z, Kinoshita T, et al. Prevalence of dementia and distribution of ApoE alleles in Japanese centenarians: an almost-complete survey in Yamanashi Prefecture, Japan. J Am Geriatr Soc 1996;44:151-155.
17. Matsuda H, Yagishita A, Tsuji S, Hisada K. A quantitative approach to technetium-99m ethyl cysteinate dimer: a comparison with technetium-99m hexamethylpropylene amine oxime. Eur J Nucl Med 1995;22:633-637.
18. 99mTc-bicisate in the human brain after intracarotid injection. J Cereb Blood Flow Metab 1994;14(suppl 1):S19-S27.
19. Matsuda H, Kanetaka H, Ohnishi T, et al. Brain SPECT abnormalities in Alzheimer's disease before and after atrophy correction. Eur J Nucl Med 2002;29:1502-1505.
20. Mueller-Gaertner HW, Links JM, Prince JL, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992;12:571-583.
21. Ashburner J, Friston KJ. Voxel-based morphometry - the methods. Neuroimage 2000;11:805-821.
22. Ibanez V, Pietrini P, Alexander GE, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998;50:1585-1593.
23. Talairach J, Tournoux P. Co-planar sterotactic atlas of the human brain. Stuttgart, Germany: Tieme; 1988.
24. Ohnishi T, Matsuda H, Hashimoto T, et al. Abnormal regional cerebral blood flow in childhood autism. Brain 2000;123:1838-1844.
25. Meltzer CC, Kinahan PE, Greer PJ, et al. Comparative evaluation of MR-based partial volume correction schemes for PET. J Nucl Med 1999;40:2053-2065.
26. Matsuda H, Kitayama N, Ohnishi T, et al. Longitudinal evaluation of both morphological and functional changes in the same individuals with Alzheimer's disease. J Nucl Med 2002;43:304-311.
27. Minoshima S, Foster NL, Kuhl DE. Posterior cingulate cortex in Alzheimer's disease. Lancet 1994;344:895.
28. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl D. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94.
29. 150 positron emission tomography. Eur J Nucl Med 1997;24:670-673.
30. Kogure D, Matsuda H, Ohnishi T, et al. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT J Nucl Med 2000;41:1155-1162.
31. 2 measured by positron emission tomography. J Cereb Blood Flow Metab 1994;14(suppl 1):S66-S75.
32. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. N Engl J Med 1996;334:752-758.
33. Small GW, Ercoli LM, Silverman DHS, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci US A 2000;97:6037-6042.
34. Lehtovirta M, Kuikka J, Helisalmi S, et al. Longitudinal SPECT study in Alzheimer's disease: relation to apolipoprotein E polymorphism. J Neurol Neurosurg Psychiatry 1998;64:742-746.
35. Corder EH, Jelic V, Basun H, et al. No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. Arch Neurol 1997;54:273-277.
36. Hirono N, Mori E, Yasuda M, Ishii K, et al. Lack of association of apolipoprotein E ε4 allele dose with cerebral glucose metabolism in Alzheimer disease. Alzheimer Dis Assoc Disord 1998;12:362-367.
37. Craft S, Teri L, Edland SD, Kukull WA, et al. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. Neurology 1998;51:149-153.
38. Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 1996;47:444-448.
39. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease. Ann Neurol 1996;39:62-70.
40. Slooter AJ, Houwing-Duistermaat JJ, van Harskamp F, et al. Apolipoprotein E genotype and progression of Alzheimer's disease: the Rotterdam Study. J Neurol 1999;246:304-308.
41. Frisoni GB, Govoni S, Geroldi C, et al. Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. Ann Neurol 1995;37:596-604.
42. Stern Y, Brandt J, Albert M, et al. The absence of an apolipoprotein ε4 allele is associated with a more aggressive form of Alzheimer disease. Ann Neurol 1997;41:615-620.
43. Smith GS, Leon ML, George AE, et al. Topography of crosssectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. Arch Neurol 1992;49:1142-1150.
44. Brown DRP, Hunter R, Wyper DJ, et al. Longitudinal changes in cognitive function and regional cerebral function in Alzheimer's disease: a SPECT blood flow study. J Psychiatr Res 1996;30:109-126.
45. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273:942-947.
46. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E ε4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A 2001;98:3334-3339.
47. Hogh P, Knudsen GM, Kjaer KH, Jorgensen OS, Paulson OB, Waldemar G. Single photon emission computed tomography and apolipoprotein E in Alzheimer's disease: impact of the epsilon 4 allele on regional cerebral blood flow. J Geriatr Psychiatry Neurol 2001;14:42-51.